Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
18
11
2019
accepted:
19
02
2020
revised:
17
02
2020
pubmed:
7
3
2020
medline:
5
1
2021
entrez:
6
3
2020
Statut:
ppublish
Résumé
Hyperleukocytosis in acute myeloid leukemia (AML) is associated with inferior outcomes. There is limited high quality evidence to support the benefits of leukapheresis. We retrospectively collected data from patients with newly-diagnosed AML who presented with a white cell count (WBC) >50 × 10
Identifiants
pubmed: 32132655
doi: 10.1038/s41375-020-0783-3
pii: 10.1038/s41375-020-0783-3
pmc: PMC8155811
mid: NIHMS1564245
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3149-3160Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR002002
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009512
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016359
Pays : United States
Références
Rollig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015;125:3246–52.
doi: 10.1182/blood-2014-10-551507
Greenwood MJ, Seftel MD, Richardson C, Barbaric D, Barnett MJ, Bruyere H, et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma. 2006;47:1245–52.
doi: 10.1080/10428190600572673
Marbello L, Ricci F, Nosari AM, Turrini M, Nador G, Nichelatti M, et al. Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature. Leuk Res. 2008;32:1221–7.
doi: 10.1016/j.leukres.2008.01.004
Porcu P, Danielson CF, Orazi A, Heerema NA, Gabig TG, McCarthy LJ. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol. 1997;98:433–6.
doi: 10.1046/j.1365-2141.1997.1943011.x
De Santis GC, de Oliveira LC, Romano LG, Almeida Prado Bde P Jr, Simoes BP, Rego EM, et al. Therapeutic leukapheresis in patients with leukostasis secondary to acute myelogenous leukemia. J Clin Apher. 2011;26:181–5.
doi: 10.1002/jca.20290
Porcu P, Cripe LD, Ng EW, Bhatia S, Danielson CM, Orazi A, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma. 2000;39:1–18.
doi: 10.3109/10428190009053534
Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–74.
doi: 10.1182/blood-2009-07-235358
Zuckerman T, Ganzel C, Tallman MS, Rowe JM. How I treat hematologic emergencies in adults with acute leukemia. Blood. 2012;120:1993–2002.
doi: 10.1182/blood-2012-04-424440
Bruserud O, Liseth K, Stamnesfet S, Cacic DL, Melve G, Kristoffersen E, et al. Hyperleukocytosis and leukocytapheresis in acute leukaemias: experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia. Transfus Med. 2013;23:397–406.
doi: 10.1111/tme.12067
Bug G, Anargyrou K, Tonn T, Bialleck H, Seifried E, Hoelzer D, et al. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis. Transfusion. 2007;47:1843–50.
doi: 10.1111/j.1537-2995.2007.01406.x
Giles FJ, Shen Y, Kantarjian HM, Korbling MJ, O’Brien S, Anderlini P, et al. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival. Leuk Lymphoma. 2001;42:67–73.
doi: 10.3109/10428190109097677
Thiebaut A, Thomas X, Belhabri A, Anglaret B, Archimbaud E. Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis. Ann Hematol. 2000;79:501–6.
doi: 10.1007/s002770000162
Oberoi S, Lehrnbecher T, Phillips B, Hitzler J, Ethier MC, Beyene J, et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. Leuk Res. 2014;38:460–8.
doi: 10.1016/j.leukres.2014.01.004
Berber I, Kuku I, Erkurt MA, Kaya E, Bag HG, Nizam I, et al. Leukapheresis in acute myeloid leukemia patients with hyperleukocytosis: a single center experience. Transfus Apher Sci. 2015;53:185–90.
doi: 10.1016/j.transci.2015.03.015
Choi MH, Choe YH, Park Y, Nah H, Kim S, Jeong SH, et al. The effect of therapeutic leukapheresis on early complications and outcomes in patients with acute leukemia and hyperleukocytosis: a propensity score-matched study. Transfusion. 2018;58:208–16.
doi: 10.1111/trf.14329
Chang MC, Chen TY, Tang JL, Lan YJ, Chao TY, Chiu CF, et al. Leukapheresis and cranial irradiation in patients with hyperleukocytic acute myeloid leukemia: no impact on early mortality and intracranial hemorrhage. Am J Hematol. 2007;82:976–80.
doi: 10.1002/ajh.20939
Inaba H, Fan Y, Pounds S, Geiger TL, Rubnitz JE, Ribeiro RC, et al. Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. Cancer. 2008;113:522–9.
doi: 10.1002/cncr.23581
Stahl M, Pine A, Hendrickson JE, Litzow MR, Luger SM, Stone RM, et al. Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey. Leuk Lymphoma. 2018;59:1–4.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.
doi: 10.1182/blood-2016-03-643544
Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.
doi: 10.1182/blood-2016-08-733196
Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–65.
doi: 10.1182/blood-2009-11-254441
Breems DA, Van Putten WL, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KB, Mellink CH, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26:4791–7.
doi: 10.1200/JCO.2008.16.0259
Shallis RM, Stahl M, Wei W, et al. Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. Leuk Lymphoma. 2020;1–6. https://doi.org/10.1080/10428194.2020.1728753 [published online ahead of print, 26 Feb 2020].
Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642–9.
doi: 10.1200/JCO.2003.04.036
Buuren Sv, Groothuis-Oudshroon K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1–67.
Sorita A, Ahmed A, Starr SR, Thompson KM, Reed DA, Prokop L, et al. Off-hour presentation and outcomes in patients with acute myocardial infarction: systematic review and meta-analysis. BMJ. 2014;348:f7393.
doi: 10.1136/bmj.f7393
Kostis WJ, Demissie K, Marcella SW, Shao YH, Wilson AC, Moreyra AE, et al. Weekend versus weekday admission and mortality from myocardial infarction. N Engl J Med. 2007;356:1099–109.
doi: 10.1056/NEJMoa063355
Janszky I, Ahnve S, Ljung R. Weekend versus weekday admission and stroke outcome in Sweden from 1968 to 2005. Stroke. 2007;38:e94. author reply e95.
doi: 10.1161/STROKEAHA.107.491449
Reeves MJ, Smith E, Fonarow G, Hernandez A, Pan W, Schwamm LH, et al. Off-hour admission and in-hospital stroke case fatality in the get with the guidelines-stroke program. Stroke. 2009;40:569–76.
doi: 10.1161/STROKEAHA.108.519355
Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, et al. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. 2015;168:646–53.
doi: 10.1111/bjh.13189